Recent Finacing
Recent Raise
Epsilogen develops IgE therapeutics for solid tumors, advancing MOv18 IgE anti-FRα through GMP manufacture and Phase Ib planning after Phase I safety data, while developing IgE bispecifics and IgEGs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
